Revance Therapeutics Inc.
Division of ReVance Therapeutics Inc.
www.revance.com
Latest From Revance Therapeutics Inc.
Asia Deal Watch: ReVance Licenses Chinese Rights To Botox Competitor To Fosun
With Phase III data in 2,800 patients for reducing frown lines, ReVance anticipates filing RT002 for US approval in 2019. ABL licenses two bispecific antibody candidates to TRIGR, while Sun looks to expand in dermatology with Pola buyout.
Medical Aesthetics: A Untapped Pharma Market With Incoming Competition
Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.
Medical Aesthetics: A Untapped Pharma Market With Incoming Competition
Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.
Allergan Buys Bonti, Releases New Data In Defense Of 'Iconic' Botox Brand
Allergan declared that no other brand is more 'iconic' than Botox, during its medical aesthetics investor event, but the company also revealed several defensive moves to protect the neurotoxin's status, including the acquisition of fast-acting, short duration toxin maker Bonti.
Company Information
- Industry
-
Biotechnology
- Large Molecule
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
- Topical Delivery
-
Drug Delivery
- Therapeutic Areas
- Dermatology
- Neurology, Nervous System
- Alias(es)
- Essentia Biosystems Inc.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- ReVance Therapeutics Inc.
- Senior Management
-
Daniel Browne, Pres. & CEO
Lauren Silvernail, CFO & Chief Business Officer
Todd Zavodnick, Chief Commercial Officer
Abhay Joshi, PhD, COO
Ben Putman, VP, Digital - Contact Info
-
Revance Therapeutics Inc.
Phone: (510) 742-3400
7555 Gateway Blvd.
Newark, CA 94560
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice